ClinicalTrials.gg
CompletedNCT04760314ADhere-JUpdated Aug 23, 2023Results posted

A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis

A Phase 3 interventional study of Lebrikizumab and Placebo in Dermatitis, Atopic, Dermatitis and Eczema, sponsored by Eli Lilly and Company. Completed at 37 sites in Japan. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-08-23.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
286
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing lebrikizumab in Dermatitis, Atopic — 4 open to participants now, 7 under way, 4 of them phase 3. lebrikizumab · Dermatitis, Atopic.

Enrollment
9th of 24
286 · median 252
Started
2021
with 1 other
Phase 3
17 of 24
2 open now
Registered
10th of 24
by date
Lead sponsor
14 of 24
Eli Lilly and Company

Among the 24 studies testing lebrikizumab in Dermatitis, Atopic, this one is the 9th largest by enrollment, is one of 2 that started in 2021, is one of 17 in phase 3, and was the 10th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 24 studies testing lebrikizumab in Dermatitis, Atopic are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About lebrikizumab

lebrikizumab: first FDA approval 2024 (EBGLYSS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing lebrikizumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in combination with a topical corticosteroids in Japanese participants with atopic dermatitis.

03

Conditions studied

  • Dermatitis, Atopic
  • Dermatitis
  • Eczema
  • Skin Diseases
  • Skin Diseases, Genetic

Keywords

  • Corticosteroids
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have chronic Atopic Dermatitis (AD) that has been present for ≥1 year before the screening.
  • Have moderate-to-severe AD, including all of the following:

    • EASI score ≥16 at the baseline
    • IGA score ≥3 (scale of 0 to 4) at the baseline
    • AD involvement on ≥10% of Body Surface Area (BSA) at the baseline
  • Have a documented history provided by a physician and/or investigator of inadequate response to existing topical medications within 6 months preceding screening as defined by at least 1 of the following:

    • Inability to achieve good disease control, defined as mild disease or better (for example, IGA ≤2) after use of at least a medium-potency topical (TCS) for at least 4 weeks, or for the maximum duration recommended by the product prescribing information (for example, 14 days for super-potent TCS), whichever is shorter. Topical corticosteroids may be used with or without Topical calcineurin inhibitors (TCI) and/or topical Janus Kinase (JAK) inhibitors.
    • Participants who failed systemic therapies intended to treat AD within 6 months preceding screening, such as cyclosporine, methotrexate (MTX), azathioprine, and mycophenolate mofetil (MMF), will also be considered as surrogates for having inadequate response to topical therapy.
  • Body weight ≥40 kilogram (kg)

Exclusion criteria

Exclusion Criteria:

  • Have a history of anaphylaxis
  • Have uncontrolled chronic disease that might require bursts of oral for example, comorbid severe uncontrolled asthma within the past 12 months requiring systemic corticosteroid treatment or hospitalization for >24 hours at baseline.
  • Have an active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before the baseline or superficial skin infections within 1 week before the baseline.
  • Evidence of acute or chronic hepatitis or known liver cirrhosis.
  • Have a history of pneumocystis pneumonia (PCP) or a positive beta-D-glucan test at screening and a confirmed diagnosis of PCP.
  • Have a history of (HIV) infection or positive HIV serology at screening.
  • Have presence of skin comorbidities (for example, sclerosis, psoriasis, or lupus erythematosus) that may interfere with study assessments.
  • Have presence of significant uncontrolled neuropsychiatric disorder.
  • Have been exposed to a within 12 weeks prior to baseline or are expected to need/receive a live vaccine during the study or up to 125 days after the last dose of study drug.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
286 participants (actual)

Study arms

  • Experimental
    Lebrikizumab 250 mg Every 4 weeks (Q4W)

    Participants received 500 mg of Lebrikizumab (2 x 250 mg) subcutaneous (SC) injections as a loading dose at Baseline followed by 250 mg of Lebrikizumab administered SC Q4W from Week 4 until Week 12, in combination with topical corticosteroid. Week 16 responders entered maintenance period and continued with the same treatment. Week 16 non responders entered Escape Arm and received Lebrikizumab 250 mg Q2W until Week 68.

    Drug: Lebrikizumab · Drug: Topical Corticosteroid

  • Experimental
    Lebrikizumab 250 mg Every 2 weeks (Q2W)

    Participants received 500 mg of Lebrikizumab (2 x 250 mg) SC injections as a loading dose at Baseline and Week 2 followed by 250 mg of Lebrikizumab administered SC Q2W from Week 4 until Week 14, in combination with topical corticosteroid. Week 16 responders entered maintenance period and were randomly allocated to receive 250 mg lebrikizumab Q2W or 250 mg lebrikizumab Q4W, in a 1:1 ratio. Week 16 non responders entered Escape Arm and received Lebrikizumab 250 mg Q2W until Week 68.

    Drug: Lebrikizumab · Drug: Topical Corticosteroid

  • Placebo comparator
    Placebo

    Participants received two SC injections of Placebo as a loading dose at Baseline in combination with topical corticosteroid and Week 2 followed by a single injection Q2W from Week 4 until Week 14. Week 16 responders entered maintenance period and continued with the same treatment. Week 16 non responders entered Escape Arm and received Lebrikizumab 250 mg Q2W until Week 68.

    Drug: Placebo · Drug: Topical Corticosteroid

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With an Investigators Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16

    The IGA measures the investigator's global assessment of the participant's overall severity of their atopic dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.

    Time frame: Baseline to Week 16

  2. Percentage of Participants Achieving Eczema Area Severity Index-75 (EASI-75) (≥75% Reduction in EASI Score) at Week 16

    The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent, i.e., percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI-75 score was obtained by weight-averaging these 4 scores and will range from 0 (none) to 72 (severe). The EASI-75 responder is defined as a participant who achieves a ≥ 75% improvement from baseline in the EASI score.

    Time frame: Week 16

Secondary outcomes

  1. Percent Change in Eczema Area Severity Index (EASI) Score From Baseline to Week 16

    The EASI assesses objective physician estimates of 2 dimensions of AD - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). Least Square (LS) Mean was calculated using ANCOVA model with treatment, stratification factors of geographic region, age group, baseline IGA score (IGA 3 versus 4) as fixed factors baseline value as covariate.

    Time frame: Baseline to Week 16

  2. Percentage of Participants Achieving EASI-90 at Week 16

    The EASI assesses objective physician estimates of 2 dimensions of AD - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI-90 responder is defined as a participant who achieves a ≥ 90% reduction from baseline in the EASI score.

    Time frame: Week 16

  3. Percentage of Participants With an Itch Numeric Rating Scale (NRS) Score of ≥4-points at Baseline Who Achieve A ≥4-point Reduction From Baseline to Week 1

    The Itch Numeric Rating Scale (NRS) is a an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

    Time frame: Baseline to Week 1

  4. Percentage of Participants With an Itch NRS Score of ≥4-points at Baseline Who Achieve A ≥4-point Reduction From Baseline to Week 2

    The Itch Numeric Rating Scale (NRS) is a an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

    Time frame: Baseline to Week 2

  5. Percentage of Participants With an Itch NRS Score of ≥4-points at Baseline Who Achieve A ≥4-point Reduction From Baseline to Week 4

    The Itch Numeric Rating Scale (NRS) is a an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

    Time frame: Baseline to Week 4

  6. Percentage of Participants With an Itch NRS Score of ≥4-points at Baseline Who Achieve A ≥4-point Reduction From Baseline to Week 16

    The Itch Numeric Rating Scale (NRS) is a an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

    Time frame: Baseline to Week 16

07

Results

Posted Aug 23, 2023

Participant flow

Induction period (16-weeks): Participants were randomly assigned to 250mg Lebrikizumab every 2 weeks (Q2W) or 250mg Lebrikizumab every 4 weeks (Q4W) or Placebo. Maintenance period (52-weeks): At week 16, responders from 250mg Lebrikizumab Q2W were re-randomised to 250mg Lebrikizumab Q2W and 250mg Lebrikizumab Q4W; responders from 250mg Lebrikizumab Q4W or Placebo arms continued with same treatment. Responders were defined as having an IGA of 0 or 1 or a 75% reduction in EASI (EASI-75).

Induction Period
Participant flow — Induction Period
MilestoneInduction - PlaceboInduction - Lebrikizumab 250mg Q4WInduction - Lebrikizumab 250mg Q2WMaintenance Blinded Period - Placebo Responder/PlaceboMaintenance Blinded Period - Lebrikizumab Q4W Responder/Lebrikizumab Q4WMaintenance Blinded Period - Lebrikizumab Q2W Responder/ Lebrikizumab Q4WMaintenance Blinded Period - Lebrikizumab Q2W Responder/Lebrikizumab Q2WEscape Arm Week 16 - Maintenance Open Label - Placebo Non Responder/Lebrikizumab 250 mg Q2WEscape Arm Week 16 Maintenance Open Label-Lebrikizumab 250mg Q4W Nonresponder/Lebrikizumab 250mg Q2WEscape Arm Week 16 Maintenance Open Label-Lebrikizumab 250mg Q2W Nonresponder/Lebrikizumab 250mg Q2WEscape Arm Week 20 to 64 Maintenance Open Label Lebrikizumab 250 Q2W
Started828112300000000
Received at least one dose of study drug828112300000000
Completed828012000000000
Not completed01300000000
Withdrew: Withdrawal by subject01100000000
Withdrew: Adverse event00200000000
Maintenance Blinded Period
Participant flow — Maintenance Blinded Period
MilestoneInduction - PlaceboInduction - Lebrikizumab 250mg Q4WInduction - Lebrikizumab 250mg Q2WMaintenance Blinded Period - Placebo Responder/PlaceboMaintenance Blinded Period - Lebrikizumab Q4W Responder/Lebrikizumab Q4WMaintenance Blinded Period - Lebrikizumab Q2W Responder/ Lebrikizumab Q4WMaintenance Blinded Period - Lebrikizumab Q2W Responder/Lebrikizumab Q2WEscape Arm Week 16 - Maintenance Open Label - Placebo Non Responder/Lebrikizumab 250 mg Q2WEscape Arm Week 16 Maintenance Open Label-Lebrikizumab 250mg Q4W Nonresponder/Lebrikizumab 250mg Q2WEscape Arm Week 16 Maintenance Open Label-Lebrikizumab 250mg Q2W Nonresponder/Lebrikizumab 250mg Q2WEscape Arm Week 20 to 64 Maintenance Open Label Lebrikizumab 250 Q2W
Started000113833320000
Received at least one dose of study drug000113833320000
Completed00093527270000
Not completed00023650000
Withdrew: Withdrawal by subject00012120000
Withdrew: Enrolled to escape arm00010430000
Withdrew: Assigned treatment by mistake00001000000
Withdrew: Protocol deviation00000100000
Maintenance Open Label Escape Arm
Participant flow — Maintenance Open Label Escape Arm
MilestoneInduction - PlaceboInduction - Lebrikizumab 250mg Q4WInduction - Lebrikizumab 250mg Q2WMaintenance Blinded Period - Placebo Responder/PlaceboMaintenance Blinded Period - Lebrikizumab Q4W Responder/Lebrikizumab Q4WMaintenance Blinded Period - Lebrikizumab Q2W Responder/ Lebrikizumab Q4WMaintenance Blinded Period - Lebrikizumab Q2W Responder/Lebrikizumab Q2WEscape Arm Week 16 - Maintenance Open Label - Placebo Non Responder/Lebrikizumab 250 mg Q2WEscape Arm Week 16 Maintenance Open Label-Lebrikizumab 250mg Q4W Nonresponder/Lebrikizumab 250mg Q2WEscape Arm Week 16 Maintenance Open Label-Lebrikizumab 250mg Q2W Nonresponder/Lebrikizumab 250mg Q2WEscape Arm Week 20 to 64 Maintenance Open Label Lebrikizumab 250 Q2W
Started00000007142558
Received at least one dose of study drug00000007142558
Completed00000006340487
Not completed00000008271
Withdrew: Withdrawal by subject00000001011
Withdrew: Lack of efficacy00000005150
Withdrew: Lost to follow-up00000002000
Withdrew: Adverse event00000000110

Outcome measures

PrimaryPercentage of Participants With an Investigators Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16

The IGA measures the investigator's global assessment of the participant's overall severity of their atopic dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.

Time frame:
Baseline to Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With an Investigators Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16
Percentage of participantsInduction - PlaceboInduction - Lebrikizumab 250 mg Q4WInduction - Lebrikizumab 250 mg Q2W
Percentage of Participants With an Investigators Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 166.1 (0.9 to 11.3)29.1 (19.2 to 39.1)33.4 (25.0 to 41.8)
Statistical analysis
  • Induction - Placebo vs Induction - Lebrikizumab 250 mg Q4W · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 22.6 · 95% CI 11.6 to 33.6
  • Induction - Placebo vs Induction - Lebrikizumab 250 mg Q2W · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 27.3 · 95% CI 17.5 to 37.0
PrimaryPercentage of Participants Achieving Eczema Area Severity Index-75 (EASI-75) (≥75% Reduction in EASI Score) at Week 16

The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent, i.e., percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI-75 score was obtained by weight-averaging these 4 scores and will range from 0 (none) to 72 (severe). The EASI-75 responder is defined as a participant who achieves a ≥ 75% improvement from baseline in the EASI score.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Eczema Area Severity Index-75 (EASI-75) (≥75% Reduction in EASI Score) at Week 16
Percentage of participantsInduction - PlaceboInduction - Lebrikizumab 250 mg Q4WInduction - Lebrikizumab 250 mg Q2W
Percentage of Participants Achieving Eczema Area Severity Index-75 (EASI-75) (≥75% Reduction in EASI Score) at Week 1613.4 (6.0 to 20.8)47.2 (36.3 to 58.1)51.2 (42.3 to 60.1)
Statistical analysis
  • Induction - Placebo vs Induction - Lebrikizumab 250 mg Q4W · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 33.2 · 95% CI 20.6 to 45.8
  • Induction - Placebo vs Induction - Lebrikizumab 250 mg Q2W · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 37.6 · 95% CI 26.2 to 49.0
SecondaryPercent Change in Eczema Area Severity Index (EASI) Score From Baseline to Week 16

The EASI assesses objective physician estimates of 2 dimensions of AD - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). Least Square (LS) Mean was calculated using ANCOVA model with treatment, stratification factors of geographic region, age group, baseline IGA score (IGA 3 versus 4) as fixed factors baseline value as covariate.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · Percent change
Percent Change in Eczema Area Severity Index (EASI) Score From Baseline to Week 16
Percent changeInduction - PlaceboInduction - Lebrikizumab 250 mg Q4WInduction - Lebrikizumab 250 mg Q2W
Percent Change in Eczema Area Severity Index (EASI) Score From Baseline to Week 16-25.25 ± 4.765-59.74 ± 4.920-64.23 ± 4.402
Statistical analysis
  • Induction - Placebo vs Induction - Lebrikizumab 250 mg Q4W · ANCOVA · p = <0.001 · Ls mean difference: -34.50 · 95% CI -44.1 to -24.9
  • Induction - Placebo vs Induction - Lebrikizumab 250 mg Q2W · ANCOVA · p = <0.001 · Ls mean difference: -38.99 · 95% CI -47.7 to -30.3
SecondaryPercentage of Participants Achieving EASI-90 at Week 16

The EASI assesses objective physician estimates of 2 dimensions of AD - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI-90 responder is defined as a participant who achieves a ≥ 90% reduction from baseline in the EASI score.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving EASI-90 at Week 16
Percentage of participantsInduction - PlaceboInduction - Lebrikizumab 250 mg Q4WInduction - Lebrikizumab 250 mg Q2W
Percentage of Participants Achieving EASI-90 at Week 169.8 (3.3 to 16.2)28.4 (18.6 to 38.3)34.3 (25.9 to 42.7)
Statistical analysis
  • Induction - Placebo vs Induction - Lebrikizumab 250 mg Q4W · Cochran-Mantel-Haenszel · p = 0.003 · Risk difference (rd): 18.4 · 95% CI 6.8 to 29.9
  • Induction - Placebo vs Induction - Lebrikizumab 250 mg Q2W · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 24.2 · 95% CI 13.9 to 34.5
SecondaryPercentage of Participants With an Itch Numeric Rating Scale (NRS) Score of ≥4-points at Baseline Who Achieve A ≥4-point Reduction From Baseline to Week 1

The Itch Numeric Rating Scale (NRS) is a an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

Time frame:
Baseline to Week 1
Reported as:
Number · Percentage of participants
Percentage of Participants With an Itch Numeric Rating Scale (NRS) Score of ≥4-points at Baseline Who Achieve A ≥4-point Reduction From Baseline to Week 1
Percentage of participantsInduction - PlaceboInduction - Lebrikizumab 250 mg Q4WInduction - Lebrikizumab 250 mg Q2W
Percentage of Participants With an Itch Numeric Rating Scale (NRS) Score of ≥4-points at Baseline Who Achieve A ≥4-point Reduction From Baseline to Week 10 (0 to 0)0 (0 to 0)1.3 (0.0 to 3.7)
Statistical analysis
  • Induction - Placebo vs Induction - Lebrikizumab 250 mg Q2W · Cochran-Mantel-Haenszel · p = 0.404 · Risk difference (rd): 1.2 · 95% CI -1.2 to 3.6
SecondaryPercentage of Participants With an Itch NRS Score of ≥4-points at Baseline Who Achieve A ≥4-point Reduction From Baseline to Week 2

The Itch Numeric Rating Scale (NRS) is a an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

Time frame:
Baseline to Week 2
Reported as:
Number · Percentage of participants
Percentage of Participants With an Itch NRS Score of ≥4-points at Baseline Who Achieve A ≥4-point Reduction From Baseline to Week 2
Percentage of participantsInduction - PlaceboInduction - Lebrikizumab 250 mg Q4WInduction - Lebrikizumab 250 mg Q2W
Percentage of Participants With an Itch NRS Score of ≥4-points at Baseline Who Achieve A ≥4-point Reduction From Baseline to Week 20 (0.0 to 0.0)1.7 (0.0 to 5.0)3.8 (0.0 to 7.9)
Statistical analysis
  • Induction - Placebo vs Induction - Lebrikizumab 250 mg Q4W · Cochran-Mantel-Haenszel · p = 0.294 · Risk difference (rd): 1.8 · 95% CI -1.6 to 5.1
  • Induction - Placebo vs Induction - Lebrikizumab 250 mg Q2W · Cochran-Mantel-Haenszel · p = 0.138 · Risk difference (rd): 3.7 · 95% CI -0.5 to 7.8
SecondaryPercentage of Participants With an Itch NRS Score of ≥4-points at Baseline Who Achieve A ≥4-point Reduction From Baseline to Week 4

The Itch Numeric Rating Scale (NRS) is a an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

Time frame:
Baseline to Week 4
Reported as:
Number · Percentage of participants
Percentage of Participants With an Itch NRS Score of ≥4-points at Baseline Who Achieve A ≥4-point Reduction From Baseline to Week 4
Percentage of participantsInduction - PlaceboInduction - Lebrikizumab 250 mg Q4WInduction - Lebrikizumab 250 mg Q2W
Percentage of Participants With an Itch NRS Score of ≥4-points at Baseline Who Achieve A ≥4-point Reduction From Baseline to Week 40 (0.0 to 0.0)8.5 (1.4 to 15.6)16.3 (8.2 to 24.3)
Statistical analysis
  • Induction - Placebo vs Induction - Lebrikizumab 250 mg Q4W · Cochran-Mantel-Haenszel · p = 0.013 · Risk difference (rd): 9.2 · 95% CI 1.8 to 16.5
  • Induction - Placebo vs Induction - Lebrikizumab 250 mg Q2W · Cochran-Mantel-Haenszel · p = 0.001 · Risk difference (rd): 16.2 · 95% CI 8.1 to 24.3
SecondaryPercentage of Participants With an Itch NRS Score of ≥4-points at Baseline Who Achieve A ≥4-point Reduction From Baseline to Week 16

The Itch Numeric Rating Scale (NRS) is a an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

Time frame:
Baseline to Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With an Itch NRS Score of ≥4-points at Baseline Who Achieve A ≥4-point Reduction From Baseline to Week 16
Percentage of participantsInduction - PlaceboInduction - Lebrikizumab 250 mg Q4WInduction - Lebrikizumab 250 mg Q2W
Percentage of Participants With an Itch NRS Score of ≥4-points at Baseline Who Achieve A ≥4-point Reduction From Baseline to Week 163.3 (0.0 to 7.9)23.8 (12.9 to 34.7)32.7 (22.4 to 43.0)
Statistical analysis
  • Induction - Placebo vs Induction - Lebrikizumab 250 mg Q4W · Cochran-Mantel-Haenszel · p = 0.001 · Risk difference (rd): 20.6 · 95% CI 8.7 to 32.4
  • Induction - Placebo vs Induction - Lebrikizumab 250 mg Q2W · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 29.2 · 95% CI 17.9 to 40.4

Adverse events

Collected over Baseline Up To Week 68.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Induction - Placebo0/82 (0%)2/82 (2.4%)52/82 (63.4%)
Induction - Lebrikizumab 250mg Q4W0/81 (0%)0/81 (0%)49/81 (60.5%)
Induction - Lebrikizumab 250mg Q2W0/123 (0%)1/123 (0.8%)93/123 (75.6%)
Maintenance Blinded Period - Lebrikizumab Q4W Responder/Lebrikizumab Q4W0/38 (0%)1/38 (2.6%)31/38 (81.6%)
Maintenance Blinded Period - Lebrikizumab Q2W Responder/ Lebrikizumab Q4W0/33 (0%)0/33 (0%)25/33 (75.8%)
Maintenance Blinded Period - Lebrikizumab Q2W Responder/Lebrikizumab Q2W0/32 (0%)1/32 (3.1%)29/32 (90.6%)
Maintenance Blinded Period - Placebo Responder/Placebo0/11 (0%)0/11 (0%)10/11 (90.9%)
Escape Arm Week 16 - Maintenance Open Label - Placebo Non Responder/Lebrikizumab 250 mg Q2W0/71 (0%)1/71 (1.4%)63/71 (88.7%)
Escape Arm Week 16 Maintenance Open Label-Lebrikizumab 250mg Q4W Nonresponder/Lebrikizumab 250mg Q2W0/42 (0%)2/42 (4.8%)36/42 (85.7%)
Escape Arm Week 16 Maintenance Open Label-Lebrikizumab 250mg Q2W Nonresponder/Lebrikizumab 250mg Q2W0/55 (0%)1/55 (1.8%)49/55 (89.1%)
Escape Arm Week 20 to 64 Maintenance Open Label Lebrikizumab 250 Q2W0/8 (0%)1/8 (12.5%)6/8 (75%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventInduction - PlaceboInduction - Lebrikizumab 250mg Q4WInduction - Lebrikizumab 250mg Q2WMaintenance Blinded Period - Lebrikizumab Q4W Responder/Lebrikizumab Q4WMaintenance Blinded Period - Lebrikizumab Q2W Responder/ Lebrikizumab Q4WMaintenance Blinded Period - Lebrikizumab Q2W Responder/Lebrikizumab Q2WMaintenance Blinded Period - Placebo Responder/PlaceboEscape Arm Week 16 - Maintenance Open Label - Placebo Non Responder/Lebrikizumab 250 mg Q2WEscape Arm Week 16 Maintenance Open Label-Lebrikizumab 250mg Q4W Nonresponder/Lebrikizumab 250mg Q2WEscape Arm Week 16 Maintenance Open Label-Lebrikizumab 250mg Q2W Nonresponder/Lebrikizumab 250mg Q2WEscape Arm Week 20 to 64 Maintenance Open Label Lebrikizumab 250 Q2W
AppendicitisInfections and infestations0/820/810/1230/380/330/320/110/710/420/551/8
Ligament injuryInjury, poisoning and procedural complications0/820/810/1230/380/331/320/110/710/420/550/8
Anaphylactic reactionImmune system disorders0/820/810/1231/380/330/320/110/710/420/550/8
Hodgkin's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/820/810/1230/380/330/320/110/711/420/550/8
Tooth extractionSurgical and medical procedures0/820/810/1230/380/330/320/110/711/420/550/8
TonsillitisInfections and infestations0/820/810/1230/380/330/320/110/710/421/550/8
Covid-19Infections and infestations1/820/810/1230/380/330/320/111/710/420/550/8
Campylobacter gastroenteritisInfections and infestations1/820/810/1230/380/330/320/110/710/420/550/8
Cerebral infarctionNervous system disorders0/820/811/1230/380/330/320/110/710/420/550/8
Back painMusculoskeletal and connective tissue disorders0/820/810/1230/380/330/320/110/710/420/550/8
Most frequent other events
Showing 10 of 301
Most frequent other events
EventInduction - PlaceboInduction - Lebrikizumab 250mg Q4WInduction - Lebrikizumab 250mg Q2WMaintenance Blinded Period - Lebrikizumab Q4W Responder/Lebrikizumab Q4WMaintenance Blinded Period - Lebrikizumab Q2W Responder/ Lebrikizumab Q4WMaintenance Blinded Period - Lebrikizumab Q2W Responder/Lebrikizumab Q2WMaintenance Blinded Period - Placebo Responder/PlaceboEscape Arm Week 16 - Maintenance Open Label - Placebo Non Responder/Lebrikizumab 250 mg Q2WEscape Arm Week 16 Maintenance Open Label-Lebrikizumab 250mg Q4W Nonresponder/Lebrikizumab 250mg Q2WEscape Arm Week 16 Maintenance Open Label-Lebrikizumab 250mg Q2W Nonresponder/Lebrikizumab 250mg Q2WEscape Arm Week 20 to 64 Maintenance Open Label Lebrikizumab 250 Q2W
PyrexiaGeneral disorders13/8215/8125/1237/386/3311/323/1113/714/425/550/8
Covid-19Infections and infestations2/822/811/1237/387/334/320/1113/718/4212/552/8
Herpes simplexInfections and infestations2/821/811/1233/383/331/320/112/718/422/550/8
Conjunctivitis allergicEye disorders4/8210/8121/1235/381/334/320/1113/711/423/550/8
Skin papillomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/821/813/1232/381/331/322/113/714/421/550/8
HeadacheNervous system disorders9/823/814/1231/386/334/321/114/712/422/551/8
RhinorrhoeaRespiratory, thoracic and mediastinal disorders0/821/811/1230/381/330/322/111/710/420/550/8
AcneSkin and subcutaneous tissue disorders5/822/814/1231/386/333/321/115/713/426/551/8
DysmenorrhoeaReproductive system and breast disorders0/240/252/410/152/121/120/52/190/91/150/3
NasopharyngitisInfections and infestations2/825/817/1232/382/333/321/118/716/427/551/8

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Induction - PlaceboInduction - Lebrikizumab 250 mg Q4WInduction - Lebrikizumab 250 mg Q2WTotal
Mean34.80 ± 13.6037.80 ± 12.0235.50 ± 12.2436.00 ± 12.59
Sex: Female, Male
Sex: Female, Male(Participants)Induction - PlaceboInduction - Lebrikizumab 250 mg Q4WInduction - Lebrikizumab 250 mg Q2WTotal
Female24254190
Male585682196
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Induction - PlaceboInduction - Lebrikizumab 250 mg Q4WInduction - Lebrikizumab 250 mg Q2WTotal
Hispanic or Latino0000
Not Hispanic or Latino0000
Unknown or Not Reported8281123286
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Induction - PlaceboInduction - Lebrikizumab 250 mg Q4WInduction - Lebrikizumab 250 mg Q2WTotal
American Indian or Alaska Native0000
Asian8281123286
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)Induction - PlaceboInduction - Lebrikizumab 250 mg Q4WInduction - Lebrikizumab 250 mg Q2WTotal
Japan8281123286
08

Study locations

37 sites
  • Yanagihara dermatology clinic
    Ainokawa, Ichikawa-shi, Chiba 272-0143, Japan
  • Kawashima Dermatology Clinic
    Ichikawa-shi, Chiba 272-0033, Japan
  • Charme Clinique
    Matsudo, Chiba 270-2223, Japan
  • Yasumoto Dermatology Clinic
    Chikushino-city, Fukuoka 818-0083, Japan
  • Hino Dermatology Clinic
    Fukutsu, Fukuoka 811-3217, Japan
  • Hiroshima University Hospital
    Hiroshima-shi, Hiroshima-ken 734-8551, Japan
  • Takagi Dermatology
    Obihiro, Hokkaido 080-0013, Japan
  • Kobayashi Skin Clinic
    Sapporo-shi, Hokkaido 060-0807, Japan
  • Sapporo Skin Clinic
    Sapporo, Hokkaido 060-0063, Japan
  • Dermatology Shimizu Clinic
    Kobe, Hyogo 657-0846, Japan
  • Ibaraki Medical Center
    Inashiki-gun, Ibaraki 300-0395, Japan
  • KAJI Dermatology Clinic
    Nonoichi-shi, Ishikawa 921-8801, Japan
  • Kosugi Dermatology Clinic
    Kawasaki, Kanagawa 211-0063, Japan
  • Queen's Square Dermatology and Allergology
    Nishi-ku, Yokohama-city, Kanagawa 220-6208, Japan
  • Nomura Dermatology Clinic
    Yokohama-shi, Kanagawa 221-0825, Japan
  • Noguchi Dermatology
    Kashima-machi, Kamimashiki-gun, Kumamoto 861-3101, Japan
  • Jyouzanhihuka・Hinyoukika Clinic
    Kumamoto Shi, Kumamoto 860-0066, Japan
  • Osaka Habikino Medical Center
    Habikino, Osaka 583-8588, Japan
  • Mochida Dermatology Clinic
    Izumiotsu-shi, Osaka 595-0025, Japan
  • Kume Clinic
    Sakai City, Osaka 593-8324, Japan
  • Yoshikawa Dermatology Clinic
    Takatsuki, Osaka 569-0824, Japan
  • Sanrui Dermatology Clinic
    Ohmiya-ku,Saitama-shi, Saitama 330-0854, Japan
  • Dokkyo Medical University Hospital
    Shimotsuga-Gun, Tochigi 321 0293, Japan
  • Akihabara Skin Clinic
    Chiyoda-ku, Tokyo 101-0021, Japan
  • Sumire Dermatology Clinic
    Edogawa-ku, Tokyo 133-0057, Japan
  • Maruyama Dermatology Clinic
    Koto-ku, Tokyo 136-0074, Japan
  • Hamaguchi Skin Clinic
    Machida-shi, Tokyo 194-0013, Japan
  • Mita Dermatology Clinic
    Minato-Ku, Tokyo 108-0014, Japan
  • Tanpopo Dermatology Clinic
    Ota-ku, Tokyo 143-0023, Japan
  • Yamate Dermatological Clinic
    Shinjuku, Tokyo 169-0075, Japan
  • Yoshihara Dermatology Clinic
    Sumida-ku, Tokyo 130-0014, Japan
  • Tachikawa Dermatology Clinic
    Tachikawa-shi, Tokyo 190-0023, Japan
  • Shirasaki Clinic
    Takaoka-shi, Toyama 9330871, Japan
  • Matsuda Tomoko Dermatological Clinic
    Fukuoka, 819-0167, Japan
  • Kyoto Furitsu Medical University Hospital
    Kyoto-shi, 602 8566, Japan
  • Osaka City University Hospital
    Osaka, 545-8586, Japan
  • Goto Dermatology Clinic
    Osaka, 554-0021, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Jul 2022, 16 months.

Results were first posted in Aug 2023, 1 year after primary completion.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 16 months is below that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2021
First posted
Feb 18, 2021
StartActual
Mar 10, 2021
Primary completionActual
Jul 31, 2022
CompletionActual
Feb 1, 2023
Results first posted
Aug 23, 2023
Last update
Aug 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04760314
Responsible party
Sponsor
First posted
Feb 18, 2021
Start date
Mar 10, 2021
Primary completion
Jul 31, 2022
Completion
Feb 1, 2023
Results posted
Aug 23, 2023
Last update
Aug 23, 2023

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lebrikizumab

Start the discussion